<DOC>
	<DOCNO>NCT01868568</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare insulin degludec insulin aspart ( IDegAsp ) co-formulations separately inject , simultaneous dos insulin degludec ( insulin 454 ) insulin aspart , compare biphasic insulin aspart 30 ( NovoMixÂ® 30 ) subject type 1 diabetes mellitus . Each subject randomise four nine possible treatment arm . IDegAsp 40 , IDegAsp 45 , IDegAsp 55 IDeg high concentration explorative formulation , similar propose commercial formulation .</brief_summary>
	<brief_title>Comparison IDegAsp ( Inclusive Three Explorative Formulations ) With Insulin Degludec Insulin Aspart Separately Injected Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Glycosylated haemoglobin A1c ( HbA1c ) equal 10.0 % base central laboratory result Diagnosed type 1 diabetes treat insulin equal 12 month Body Mass Index ( BMI ) 18.0 27.0 kg/m^2 ( inclusive ) A subject history significant multiple drug allergy know suspect allergy trial product medicine chemically related trialproduct , judge Investigator A subject know hepatitis carrier Hepatitis B surface antibody , positive result test HIV antigen ( HBsAg ) Hepatitis C antibodies A subject participate trial involve investigational product within 3 month precede start dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>